


A CLOUD COMPUTING DATABASE FOR DATA EXTRACTION IN A COCHRANE REVIEW.

Britta Stordal¹, Evangelos Kapros², Steven Busschots¹, Denise Lawlor¹, Ben Doherty¹, Lesley Smith³, Bryan Hennessy⁴, Dónal O'Mathúna⁵.

1. Department of Histopathology, St James' Hospital and Trinity College Dublin, IRELAND.
2. Department of Computer Science, Trinity College Dublin, IRELAND.
3. Department of Social Work and Public Health, Brookes University Oxford, UK.
4. Department of Medical Oncology, Beaumont Hospital and Royal College of Surgeons in Ireland, IRELAND.
5. School of Nursing & Human Sciences, Dublin City University, IRELAND.



Disclosures

Conflict of Interest

“I have no actual or potential conflict of interest in relation to this presentation.”

Funding



NHS
***National Institute for
Health Research***



The National Institute for Health Research is the largest single funder of the Cochrane Gynaecological Cancer Group

Taxane monotherapy for the treatment of platinum pre-treated epithelial ovarian cancer (Review)





**THE COCHRANE
COLLABORATION®**


What is Drug Resistance?




Paclitaxel vs. Docetaxel



Taxane Weekly vs. 3-Weekly




Taxane Naive vs. Pre-treated



Platinum Resistant vs. Sensitive




Practical Problems



Practical Problems



Practical Problems




RCSI

OXFORD
BROOKES
UNIVERSITY


Cloud Computing

The practice of using a network of remote servers hosted on the Internet to store, manage, and process data, rather than a local server.

Database Design



Database Design



Google Docs

The screenshot shows the Google Docs homepage in a Mozilla Firefox browser. The browser's address bar contains the URL: `https://accounts.google.com/ServiceLogin?service=writely&passive=1209600&continue=https%3A%2F%2Fdocs.google.com%2F%23&followup=https%3A%2F%2Fdo`. The page features the Google logo at the top left and a red "SIGN UP" button at the top right. Below the logo, the word "Docs" is written in red, followed by the text "Get stuff done, together, with apps in Google Drive". A central section displays three icons: a blue document icon labeled "Docs", a green spreadsheet icon labeled "Sheets", and a yellow presentation icon labeled "Slides". To the right of these icons, the text reads: "Create, share, and collaborate on the web with documents, spreadsheets, presentations, and more." Below this text are links for "Google Drive Blog" and "Templates". On the right side of the page, there is a "Sign in" form with fields for "Email" and "Password", a "Sign in" button, a "Stay signed in" checkbox, and a link for "Can't access your account?". At the bottom left, there is a link with a Google Drive icon that says "Learn more about apps in Google Drive".



HOW TO USE: Google forms



Share this document

Invite people:

as collaborators as viewers to fill out a form ^{NEW}

How it works:



Create a form and invite people to fill it out...




...their answers will be automatically added to this spreadsheet.


[Start editing your form...](#)

Google Forms Database Design


PART A – Common Questions **PART B – Subgroup Specific Questions**



PART A – Common Questions **PART B – Subgroup Specific Questions**



Part A – Common to All Studies



Cochrane data extraction form

Taxane monotherapy for the treatment of platinum pre-treated epithelial ovarian cancer

* Required

Article ID *

42

Author, Year

Kudelka A, 1996

Name of reviewer *

Denise Lawlor

Continue »

Powered by [Google Docs](#)

[Report Abuse](#) - [Terms of Service](#) - [Additional Terms](#)



Part A – Common to All Studies

Cochrane data extraction form - Mozilla Firefox

File Edit View History Bookmarks Tools Help

Inbox - brittastordal@gmail.com - G... x Cochrane data extraction form x +

VkzcVY3LWc&edit=AE3NhGJUwguIp8id7gZaIk9dqLP5WRUB0vXLgPw7Ms3UaBG9CM7LhF15IIN47HCWFRiLhTuzalPeLNRqGWOeqS9g4RI2onLWIA&embedded=true&ifq ☆ Google

Cochrane data extraction form

Study eligibility

This section establishes if the clinical trial is eligible for the review. There are many inclusion and exclusion criteria. Use for the data:

- reporting how many papers were ineligible/eligible as a percentage
- reporting how many studies were randomised/non-randomised percentage.

What is the design of the study?

Phase I/II Non Randomised – Prospective – Eligible ▾

Are all patients in study ovarian cancer, primary peritoneal or fallopian tube cancer patients?

Yes – Ovarian cancer and primary peritoneal or Fallopian tube – Eligible ▾

Are all the ovarian cancer patients epithelial?

Yes – Eligible ▾

Are all patients in study relapsed or recurrent disease?



Part A – Common to All Studies

Cochrane data extraction form - Mozilla Firefox

File Edit View History Bookmarks Tools Help

Inbox - brittastordal@gmail.com - G... x Cochrane data extraction form x +

VkzcVY3LWc&ptok=7831207803030506186&edit=AE3NhGJUwguIp8id7gZalk9dqLP5WRUB0vXLgPw7Ms3UaBG9CM7LhFI5IIN47HCWFRiLhTuzaLPeLNRqGWoeqS9g4RI2o ☆ Google

Cochrane data extraction form

Assessment of Risk of Bias

Assessment of Risk of Bias in Included Randomised Studies

Sequence generation

Was the allocation sequence randomly generated?

- Yes
- No
- Unclear

Allocation Concealment

Was allocation adequately concealed?

- v



Part A – Common to All Studies

Cochrane data extraction form - Mozilla Firefox

File Edit View History Bookmarks Tools Help

Inbox - brittastordal@gmail.com - G... Cochrane data extraction form

VkzcVY3LWc&ptok=7831207803030506186&edit=AE3NhGJUwguIp8id7gZalk9dqLP5WRUB0vXLgPw7Ms3UaBG9CM7LhF5IIN47HCWFRiLhTuzaLPeLNRqGWoeqS9g4RI2o

Google

yes no Not Applicable

Were co-interventions similar or identical?

Additional Assessment of Risk of Bias in Included Non Randomised Studies

	Yes	No	Unclear
Were relevant details of eligibility criteria for enrolment of patients in the study provided?	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Was the group of women who received the intervention representative of patients with ovarian cancer?	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>

« Back Continue »

Powered by [Google Docs](#)

[Report Abuse](#) - [Terms of Service](#) - [Additional Terms](#)

Part A – Common to All Studies



Cochrane data extraction form

Subgroup Classifications

May have more than one per study

All Studies Epithelial Ovarian Cancer

- Paclitaxel
- Docetaxel
- Both

« Back

Continue »

Powered by [Google Docs](#)

[Report Abuse](#) - [Terms of Service](#) - [Additional Terms](#)



Part A – Common to All Studies



Cochrane data extraction form

Paclitaxel

Frequency

- Weekly
- 3 Weekly
- Both

[« Back](#) [Continue »](#)

Powered by [Google Docs](#)

[Report Abuse](#) - [Terms of Service](#) - [Additional Terms](#)



Part A – Common to All Studies



Cochrane data extraction form

Paclitaxel 3 Weekly

Pre-treated or Naïve

- Taxane Pre-Treated
- Taxane Naïve
- Both
- Unknown

« Back

Continue »

Powered by [Google Docs](#)

[Report Abuse](#) - [Terms of Service](#) - [Additional Terms](#)



Part A – Common to All Studies



Cochrane data extraction form

Paclitaxel/3 Weekly/Unknown

Platinum Resistant or Sensitive

- Platinum Resistant
- Platinum Sensitive
- Both
- Unknown

« Back

Continue »

Powered by [Google Docs](#)

[Report Abuse](#) - [Terms of Service](#) - [Additional Terms](#)



Part A – Common to All Studies



Cochrane data extraction form

Thanks!

Please submit this first part of the data extraction, more coming soon!

[« Back](#)

[Submit](#)

Never submit passwords through Google Forms.

Powered by [Google Docs](#)

[Report Abuse](#) - [Terms of Service](#) - [Additional Terms](#)



Part A – Database Output

Part A 9-7-13 - Microsoft Excel

File Home Insert Page Layout Formulas Data Review View Developer

Normal Page Layout Page Break Preview Custom Views Full Screen

Workbook Views Show

Ruler Formula Bar

Gridlines Headings

Zoom 100% Zoom to Selection

New Window Arrange All Freeze Panes Unhide

Split Hide Synchronous Scrolling Reset Window Position

View Side by Side Save Workspace Switch Windows

Macros

B6 fx 4

	A	B	C	D	E	F	G	H
1	Timestamp	Article ID	Author, Year	Name of reviewer	Are all patients in study ovarian cancer, primary peritoneal or fallopian tube cancer patients?	Is the treatment intervention taxane monotherapy?	Is the treatment given weekly or 3 weekly?	Is the tre salvage 1
2	11/29/2011 14:57:59	3	Aravantinos, 1997	Britta Stordal	Yes – Eligible	Yes Paclitaxel –	3 Weekly – Eligible	Yes – Elig
3	10/19/2012 10:17:58	3	Berkenblit, 2004	Lesley Smith	Yes – Ovarian	Yes Docetaxel –	Weekly – Eligible	Yes – Elig
4	2/8/2013 10:19:49	3		Britta Stordal	-	-	-	-
5	11/29/2011 15:09:05	4	Baird, 2010	Britta Stordal	Unknown –	Unknown –	Other – Ineligible	Unknown -
6	10/20/2012 8:18:03	4	Bruzzozone, 1996	Lesley Smith	Yes – Ovarian	Yes Paclitaxel –	-	-
7	4/2/2013 10:38:19	4	bruzzzone, 1996	Lesley Smith	Yes – Ovarian	Yes Paclitaxel –	3 Weekly – Eligible	Yes – Elig
8	11/29/2011 15:15:06	5	Balat, 1996	Britta Stordal	Yes – Eligible	Yes Paclitaxel –	Other – Ineligible	Yes – Elig
9	10/20/2012 8:55:22	5	Cantu, 2002	Lesley Smith	Yes – Ovarian	Yes Paclitaxel –	3 Weekly – Eligible	Yes – Elig
10	2/14/2012 10:23:43	6	Berkenblit, 2004	Britta Stordal	Yes – Eligible	Yes Docetaxel –	Weekly – Eligible	Yes – Elig
11	5/4/2013 9:12:19	6	Berkenblit, 2004	Britta Stordal	Yes – Ovarian	Yes Docetaxel –	Weekly – Eligible	Yes – Elig
12	10/20/2012 14:19:33	6	Du Bois, 1997	Lesley Smith	Yes – Ovarian	Yes Paclitaxel –	3 Weekly – Eligible	Yes – Elig
13	11/29/2011 15:33:52	7	Blom, 1996	Britta Stordal	Yes – Eligible	Yes Paclitaxel –	Other – Ineligible	Yes – Elig
14	1/10/2012 13:44:10	7	Dunder, 2005	Britta Stordal	Yes – Eligible	Yes Paclitaxel –	Weekly – Eligible	Yes – Elig

Ready 150%

Microsoft Excel



Part A – Consensus

Britta Steven Consensus Meeting - Microsoft Excel

File Home Insert Page Layout Formulas Data Review View Developer

Normal Page Layout Page Break Preview Custom Views Full Screen

Workbook Views

Ruler Formula Bar

Gridlines Headings

Show

Zoom 100% Zoom to Selection

Zoom

New Window Arrange All Freeze Panes Unhide

Window

View Side by Side Synchronous Scrolling Reset Window Position

Save Workspace Switch Windows Macros

E7

	Timestamp	Article ID	Author, Year	Name of reviewer	Are all patients in study ovarian cancer, primary peritoneal or fallopian tube cancer patients?	Is the treatment intervention taxane monotherapy?	Is the treatment weekly or 3 weeks?
2							
3	9/20/2012 11:57:25	3253	Piccart, 1996	Britta Stordal	Yes – Ovarian cancer and primary peritoneal or fallopian tube cancer patients?	Yes Docetaxel – Eligible	3 Weekly – Eligible
4	8/3/2012 14:34:32	3253	Piccart et.al. 1996	Steven Busschots	Yes – Ovarian cancer and primary peritoneal or fallopian tube cancer patients?	Yes Docetaxel – Eligible	3 Weekly – Eligible
5	0	1	0	0	1	1	
6	1		1	1			
7	Article Checked 25-10-12						
8							
9	9/18/2012 10:18:01	3232	Piccart, 1995	Britta Stordal	Yes – Ovarian cancer and primary peritoneal or fallopian tube cancer patients?	Yes Docetaxel – Eligible	3 Weekly – Eligible

Sheet1 Sheet2 Sheet3

Ready 150%

Microsoft Excel



Part A – Consensus

Britta Steven Consensus Meeting - Microsoft Excel

	H	I	J	K	L	M	N	O
1	Is the treatment a salvage therapy?	Start date of patient recruitment? (month, year)	End date of patient recruitment? (month, year)	Are the patients taxane pre-treated or taxane naïve?	Are all the patients platinum pre-treated?	Are all patients platinum resistant or sensitive?	Overall eligibility of study for review?	Reason ineligible
2								
3	Yes – Eligible	May, 1992	June, 1994	Taxane Naïve – Eligible	Yes – Eligible	Both – Can be separated – Eligible	Eligible	
4	Yes – Eligible	May 92	June 94	Unknown – Recruited before	Yes – Eligible	Both – Can be separated – Eligible	Eligible	
5	1	0	0	0	1	1	1	
6		1	1	0				
7				Britta's Answer Page 154 in eligibility patients excluded if paclitaxel pretreated				
8								
9	Yes – Eligible	May, 1992	December, 1992	Unknown – Recruited before	Yes – Eligible	Platinum Resistant – Eligible	Eligible	Only Pt Re Cohort Usa



Part B – Data to Separate by Subgroup

Cochrane data extraction form - P3WN - Mozilla Firefox

Inbox - brittastordal@gmail.com - G... | Cochrane data extraction form - P3WN

https://docs.google.com/spreadsheet/viewform?formkey=dDZ5cXFEeFJXTHZqOFFSYnV1bWdnUEE6MA&ifq&edit=AE3NhGlgBTCJEqJcdBbReKtzW7Y12OXCRXgn8ie1

Cochrane data extraction form - P3WN

Taxane monotherapy for the treatment of platinum pre-treated epithelial ovarian cancer
* Required

Article ID *
11

Author, Year
Bruzzone, 1996

Name of reviewer *
Britta Stordal

Continue »

Powered by [Google Docs](#)

[Report Abuse](#) - [Terms of Service](#) - [Additional Terms](#)



Part B – Data to Separate by Subgroup

Cochrane data extraction form - P3WN - Mozilla Firefox

Inbox - brittastordal@gmail.com - G... | Cochrane data extraction form - P3WN

https://docs.google.com/spreadsheet/formResponse?formkey=dDZ5cXFEeFJXTHZqOFFSYnV1bWdnUEE6MA&edit=AE3NhGLgBTCJEqJlCdBbReKtzW7Y12OXCRXgn8ieL

Cochrane data extraction form - P3WN

Patient Flow Chart through study
Include both arms of a randomised study

Not Eligible

Randomised - Paclitaxel/3 Weekly/Taxane Naïve/Platinum Resistant

Randomised - Paclitaxel/3 Weekly/Taxane Naïve/Platinum Sensitive

Randomised - Both

Response - Paclitaxel/3 Weekly/Taxane Naïve/Platinum Resistant
Number Reporting Outcomes



Part B – Data to Separate by Subgroup

Cochrane data extraction form - P3WN - Mozilla Firefox

Inbox - brittastordal@gmail.com - G... x Cochrane data extraction form - P3WN x +

https://docs.google.com/spreadsheet/formResponse?formkey=dDZ5cXFEeFJXTHZqOFFSYnV1bWdnUEE6MA&ptok=5929579905180189860&edit=AE3NhGLgBTCJEqJc

Unknown/Not Assessable - Paclitaxel/3 Weekly/Taxane Naïve/Platinum Resistant

Unknown/Not Assessable - Paclitaxel/3 Weekly/Taxane Naïve/Platinum Sensitive

Response Rate = CR + PR / n (%) - All Patients

Response Rate = CR + PR / n (%) - Paclitaxel/3 Weekly/Taxane Naïve/Platinum Resistant


Response Rate = CR + PR / n (%) - Paclitaxel/3 Weekly/Taxane Naïve/Platinum Sensitive

Powered by [Google Docs](#)

[Report Abuse](#) - [Terms of Service](#) - [Additional Terms](#)



Part B – Data to Separate by Subgroup



Saving Google Docs Links

Reference Manager 12 - [Reference List - cochrane master 3 Database: Journal Reference ID 6]

File Edit View References Tools Window Help

Ref Type* Journal

Ref ID* 6

Title A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer

Authors Berkenblit,A.; Seiden,M.V.; Matulonis,U.A.; Penson,R.T.; Krasner,C.N.; Roche,M.; Mezzetti,L.; Atkinson,T.; Cannistra,S.A.;

Pub Date* /12/2004 Other

Web/URL

File Attachments

Link to Full-text <C:\Users\Britt\Documents\Cochrane Project\Cochrane Papers PDF Files\6.pdf>

Related Links

Image(s)

Notes
Eligible - Now including Fallopian tube and primary peritoneal cancers with ovarian
<https://spreadsheets.google.com/spreadsheet/embeddedform?pli=1&hl=en&key=0Alyfn71iDYzKdDNqRGtZTkZobE1wUThpcDV5VG1CVkE&embedded=true&ifq&edit=AE3NhGKq9a5bGEDLzJGUDBCiHTf-VnerPs7fzRQYqZ4-OeLDHeivrB75COPdNy0FWkDZE-8f23ZHqq9D3aZiilNsVXs5KHZpmA>
https://spreadsheets.google.com/spreadsheet/embeddedform?pli=1&hl=en&key=0Alyfn71iDYzKdDNqRGtZTkZobE1wUThpcDV5VG1CVkE&embedded=true&ifq&edit=AE3NhGlcYu3viypAHLGaHDbyI-DivSV5bGd0tpZ7hloRZJ2FwtTp-dv9TXK6X17nMsZiWkK2sjMN_XqMnByYvGh1YJ1RfOM69A

Ref ID	Notes	Reprint	Date, primary	Authors	Title
<input type="checkbox"/> 6	Eligible - Now including Fallopian tube and primary peritoneal cancers with ovarian	In File	2004	Berkenblit,A.	A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer
<input type="checkbox"/> 7	Not Eligible - Retrospective	In File	1996	Blom,R.	Paclitaxel (Taxol) monotherapy in the treatment of platinum-resistant epithelial ovarian carcinoma
<input type="checkbox"/> 8	Not Eligible - Missing - ILL Cannot Request		1995	Bolis,G.	A multicenter randomized study of paclitaxel (PTX) vs placebo in platinum-resistant epithelial ovarian carcinoma
<input type="checkbox"/> 9	Not Eligible - Retrospective		1999	Dalis,C.	Paclitaxel in platinum-resistant epithelial ovarian carcinoma: a randomized, double-blind, placebo-controlled study

cochrane master 3

For Help, press F1

0 Marked Reference 8 of 140

NUM

Saving Google Docs Links

Reference Manager 12 - [Reference List - cochrane master 3 Database: Journal Reference ID 6]

File Edit View References Tools Window Help

New Form
<https://spreadsheets.google.com/spreadsheet/embeddedform?pli=1&hl=en&key=0Alyfn71iDYzKdEk1RU0wTTFRODJyYVVneWkzcVY3LWc&embedded=true&embedded=true&ifq&edit=AE3NhGK2u6MUGGpflI5CEsLsYhifzMMv9jWfeTPgbJOM0arJDUH5NzyM64Ytv9O0wSe87bEzaih067Hv2XL-EiREY5bVSJdQ>

Part A Consensus 04-05-13
https://spreadsheets.google.com/spreadsheet/embeddedform?pli=1&hl=en&key=0Alyfn71iDYzKdEk1RU0wTTFRODJyYVVneWkzcVY3LWc&embedded=true&embedded=true&ifq&edit=AE3NhGIbfQXdu3omiL3I9hn1tCmm6ilzfiHyZ_WoAlwviMBx-HBobqF-56rfmt0-gldgne2Szn96cvq60rYSIbSkiAEoFxtmOw

Part B
<https://docs.google.com/spreadsheet/viewform?formkey=dFR1eTlyMmwTVDNfOXUzdVUza0FRZUE6MA&ifq&edit=AE3NhGKenwcj8H-5yVqYcKgVnX-OJQ-mdCyE7Dlxti6-6jTj5aNF8zeTevEcFOSJpauh2touLbV-PEc3VYiPVaG9ToAzU22WA>

Part B Consensus 11-6-13
https://docs.google.com/spreadsheet/viewform?formkey=dFR1eTlyMmwTVDNfOXUzdVUza0FRZUE6MA&ifq&edit=AE3NhGJqRobvykZboxLm8RdY-uXfLJDf9mUf23qkgJFrLW8psAt4LaGVtROy_mVa64qCt_0RpSqCIHbm01DI1EQOgmz2a4yB2w

Keywords Cancer;

Reprint In File 19/09/13

Journal* Gynecologic Oncology

Ref ID	Notes	Reprint	Date, primary	Authors	Title
6	Eligible - Now including Fallipian 1	In File	2004	Berkenblit, A.	A phase II trial of weekly docetaxel in patients with pla
7	Not Eligible - Retrospective	In File	1996	Blom, R.	Paclitaxel (Taxol) monotherapy in the treatment of pro
8	Not Eligible - Missing - ILL Cann	On Request	1995	Bolis, G.	A multicenter randomized study of paclitaxel (PTX) vs
9	Not Eligible - Retrospective	In File	1999	Dalis, C.	Paclitaxel vs. epirubicin in the treatment of

cochrane master 3 /

0 Marked Reference 8 of 140

NUM

For Help, press F1

Consensus Data


Cochrane Part A Data 22.8.13 - Microsoft Excel

1	Timestamp	Article ID	Author, Year	Name of reviewer	Are all patients in study ovarian cancer, primary peritoneal or fallopian tube cancer patients?	Is the treatment intervention taxane monotherapy?	Is the treatment given weekly or 3 weekly?	Is the treatment salvage therapy?
2	5/4/2013 9:09:00	3047	Andersson, 1997	Britta Stordal	Yes – Ovarian cancer	Yes Paclitaxel – Eligible	Weekly – Eligible	Yes – Eligible
3	5/4/2013 9:12:19	6	Berkenblit, 2004	Britta Stordal	Yes – Ovarian cancer	Yes Docetaxel – Eligible	Weekly – Eligible	Yes – Eligible
4	5/4/2013 9:20:09	11	Bruzzone, 1996	Britta Stordal	Yes – Ovarian cancer	Yes Paclitaxel – Eligible	3 Weekly – Eligible	Yes – Eligible
5	5/4/2013 9:25:11	14	Cantu, 2002	Britta Stordal	Yes – Ovarian cancer	Yes Paclitaxel – Eligible	3 Weekly – Eligible	Yes – Eligible
6	5/4/2013 9:38:41	16	du Bois, 1997	Britta Stordal	Yes – Ovarian cancer	Yes Paclitaxel – Eligible	3 Weekly – Eligible	Yes – Eligible


Microsoft Excel



Analysis of Data - Docetaxel




Analysis of Data - Docetaxel




Analysis of Data - Docetaxel

3-Weekly Docetaxel (Taxane Pre-treated) n = 514



Weekly Docetaxel (Taxane Naive) n = 81



Z-test for Comparison = 3.47 p = 0.0003


Conclusions



- The cloud-computing database overcomes the problems of authors working in multiple locations and provides long-term storage not linked to one institution



- The database is cost-effective using Google Docs and Forms freeware and Microsoft Excel. Google Forms makes the data extraction straightforward for review authors.



- The database has made the multiple subgroups of the Cochrane review easily interrogated for the write up of the review.

Questions?

brittastordal@gmail.com